Header Ads Widget

Pancreatic cancer drug

 

🧬 NEW PANCREATIC CANCER DRUG SHOWS REMARKABLE RESULTS, OFFERING FRESH HOPE



A major breakthrough in cancer research! A new targeted drug called daraxonrasib, marketed under the brand name RASONQUE, is showing promising results against advanced pancreatic cancer.

New clinical trial findings presented on November 20, 2026, suggest that combining the daily pill with chemotherapy could dramatically reduce pancreatic tumours and help patients live longer.

In a study involving 61 patients with metastatic pancreatic cancer, tumours shrank or disappeared in 60.7% of participants. Around 8.2% experienced complete responses, meaning their tumours were no longer detectable on scans. Overall, the disease was controlled in approximately 90% of patients.

Researchers also reported that 76.6% of participants were alive one year after starting treatment.

Daraxonrasib works by targeting cancer-driving RAS proteins, particularly mutations involving KRAS, which play a major role in pancreatic cancer growth.

The drug has already received approval from the US Food and Drug Administration for certain adults with metastatic pancreatic cancer. However, the newly reported combination results come from an early-stage trial and require confirmation in larger studies.

Scientists say the findings could represent an important advance against one of the world's most difficult cancers to treat.

Drug: Daraxonrasib (RASONQUE)
Company: Revolution Medicines
Research: Phase 1/2 clinical trial
Latest findings: November 20, 2026
Study participants: 61 patients

Important: Researchers caution that the treatment is not yet proven to cure pancreatic cancer.

Post a Comment

0 Comments